Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis

被引：0
|
作者：
Osvaldo Artigalás
Tazio Vanni
Mara Helena Hutz
Patricia Ashton-Prolla
Ida Vanessa Schwartz
机构：
[1] UFRGS,Postgraduate Program in Genetics and Molecular Biology, Department of Genetics
[2] Grupo Hospitalar Conceição,Genetics Unit, Children’s Hospital
[3] GHC,Coordenação Geral de Avaliação de Tecnologias em Saúde – CGATS, Department of Science and Technology
[4] Ministry of Health,undefined
[5] Medical Genetics Service,undefined
[6] Hospital de Clinicas de Porto Alegre,undefined
[7] HCPA,undefined
来源：
BMC Medicine | / 13卷
关键词：
Adverse effects; Aromatase inhibitors; Breast cancer; Clinical outcomes; Meta-analysis; Pharmacogenetics; Systematic review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Aromatase inhibitors for PCOS: a systematic review and meta-analysis
    Misso, Marie L.
    Wong, Jennifer L. A.
    Teede, Helena J.
    Hart, Roger
    Rombauts, Luk
    Melder, Angela M.
    Norman, Robert J.
    Costello, Michael F.
    [J]. HUMAN REPRODUCTION UPDATE, 2012, 18 (03) : 301 - 312
  • [22] In silico analysis of nsSNPs in CYP19A1 gene affecting breast cancer associated aromatase enzyme
    Pavithran, Honey
    Kumavath, Ranjith
    [J]. JOURNAL OF GENETICS, 2021, 100 (02)
  • [23] In silico analysis of nsSNPs in CYP19A1 gene affecting breast cancer associated aromatase enzyme
    Honey Pavithran
    Ranjith Kumavath
    [J]. Journal of Genetics, 2021, 100
  • [24] Lack of genomic rearrangements involving the aromatase gene CYP19A1 in breast cancer
    Fukami, Maki
    Suzuki, Junichi
    Nakabayashi, Kazuhiko
    Tsunashima, Ryo
    Ogata, Tsutomu
    Shozu, Makio
    Noguchi, Shinzaburo
    [J]. BREAST CANCER, 2014, 21 (03) : 382 - 385
  • [25] CYP19A1 AMPLIFICATION PROMOTES ACQUIRED RESISTANCE TO AROMATASE INHIBITORS
    不详
    [J]. CANCER DISCOVERY, 2017, 7 (03) : 247 - 247
  • [26] Lack of genomic rearrangements involving the aromatase gene CYP19A1 in breast cancer
    Maki Fukami
    Junichi Suzuki
    Kazuhiko Nakabayashi
    Ryo Tsunashima
    Tsutomu Ogata
    Makio Shozu
    Shinzaburo Noguchi
    [J]. Breast Cancer, 2014, 21 : 382 - 385
  • [27] Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis
    Berczi, Balint
    Farkas, Nelli
    Hegyi, Peter
    Toth, Barbara
    Csupor, Dezso
    Nemeth, Balazs
    Lukacs, Anita
    Czumbel, Laszlo Mark
    Keremi, Beata
    Kiss, Istvan
    Szabo, Andrea
    Varga, Gabor
    Gerber, Gabor
    Gyongyi, Zoltan
    [J]. JOURNAL OF CLINICAL MEDICINE, 2024, 13 (06)
  • [28] Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis
    Goldvaser, Hadar
    Barnes, Tristan A.
    Seruga, Bostjan
    Cescon, David W.
    Ocana, Alberto
    Ribnikar, Domen
    Amir, Eitan
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (01) : 31 - 39
  • [29] The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta-analysis
    Zhang, Ying
    Hou, Kelu
    Liu, Fang
    Luo, Xingxian
    He, Shiyu
    Hu, Lei
    Yang, Changqing
    Huang, Lin
    Feng, Yufei
    [J]. MYCOSES, 2021, 64 (08) : 860 - 873
  • [30] Pyridine based dual binding site aromatase (CYP19A1) inhibitors
    Eissa, Ahmed G. G.
    Powell, Lauren E. E.
    Gee, Julia
    Foster, Paul A. A.
    Simons, Claire
    [J]. RSC MEDICINAL CHEMISTRY, 2023, 14 (02): : 356 - 366
12345